scholarly journals Comparison of the Whole-Body Bone Scintigraphy with Levels of the Markers of Bone Metabolism in Serum of Patients with Malignant Melanoma

2015 ◽  
Vol 5 (1) ◽  
pp. 5-11 ◽  
Author(s):  
J. Weissensteiner ◽  
E. Babusikova
Keyword(s):  
Malignant Melanoma ◽  
Bone Metastases ◽  
Bone Metabolism ◽  
Bone Scintigraphy ◽  
Type I Collagen ◽  
Whole Body ◽  
Type I ◽  
Control Subjects ◽  
Body Bone ◽  
Physiological Value

Abstract Objective. The aim of this study was to evaluate serum levels of the biochemical markers of bone metabolism: osteocalcin (OC), beta-carboxyterminal cross-linked telopeptide of type I collagen (β-CTx) with the presence of bone metastases detected by whole-body bone scintigraphy in patients with malignant melanoma. Methods. We determined the markers of bone metabolism in the serum by electrochemiluminescent immunoanalysis in 14 patients with melanoma and in 10 persons without malignant disease (control subjects). All participants were examined by whole-body bone scintigraphy using hybrid scanner of type BrightView XCT. Results. The bone metastases by whole-body bone scintigraphy were in 5 cases, probably in 3 cases and 6 patients were without bone metastases from 14 patients (4 men, 10 women). The concentration of OC in patients was lower about 25.4% in comparison with control subjects. The concentration of OC in the serum was below physiological value in 6 patients and in 4 cases with bone metastases. The concentration of β-CTx was below physiological value in 3 patients and in 2 cases with bone metastases. Conclusion. We observed lower concentration of osteocalcin in patients with malignant melanoma compared to control subjects and the lowest ostecalcin concentration was observed in patients with bone metastases. We did not observe changes in the concentration of beta-carboxyterminal cross-linked telopeptide of type I collagen compared neither to control subjects nor between patients with or without bone metastases.

scholarly journals Bone Metabolism of the Patient with a Malignant Melanoma during the Entry Examination and the Check-up of Whole-body Bone Scintigraphy

2016 ◽  
Vol 117 (2-3) ◽  
pp. 129-134
Author(s):  
Jaroslav Weissensteiner ◽  
Eva Babušíková
Keyword(s):  
Malignant Melanoma ◽  
Bone Metastases ◽  
Bone Metabolism ◽  
Bone Scintigraphy ◽  
Type I Collagen ◽  
Tumour Marker ◽  
Whole Body ◽  
Type I ◽  
Negative Finding ◽  
Body Bone

Malignant melanoma is a malignancy located predominantly in the skin and the incidence of melanoma increases. We compared the markers of bone metabolism – osteocalcin (OC), beta-carboxyterminal cross-linked telopeptide of type I collagen (β-CrossLaps, β-CTx) and tumour marker – human epididymis protein 4 (HE4) in the serum with finding during the entry examination and the check-up of whole-body bone scintigraphy of the patient with a malignant melanoma. Serum concentrations of OC, β-CTx, HE4 were determined in 1 patient (female, age 64 years) with malignant melanoma and correlated with the presence of equivocal bone metastases detected by whole-body bone scintigraphy (the entry examination and check-up after 6 months). Concentrations of bone metabolism markers decreased during six months and we observed progress in bone metastases. The change of the markers levels during the entry examination and the check-up of the whole-body bone scintigraphy with equivocal finding of bone metastases could be a sign of a possible initiating progression of malignant melanoma despite a clinically negative finding that does not prove the progression of the disease.

scholarly journals Reduced Bone Mineral Density and Increased Bone Metabolism Rate in Young Adult Patients with 21-Hydroxylase Deficiency

2006 ◽  
Vol 91 (11) ◽  
pp. 4453-4458 ◽  
Author(s):  
Mariateresa Sciannamblo ◽  
Gianni Russo ◽  
Debora Cuccato ◽  
Giuseppe Chiumello ◽  
Stefano Mora
Keyword(s):  
Bone Mineral Density ◽  
Alkaline Phosphatase ◽  
Bone Metabolism ◽  
Type I Collagen ◽  
Whole Body ◽  
Type I ◽  
Healthy Controls ◽  
Mineral Density ◽  
Specific Alkaline Phosphatase ◽  
Bone Specific Alkaline Phosphatase

Abstract Context: Patients with congenital adrenal hyperplasia (CAH) receive glucocorticoids as replacement therapy. Glucocorticoid therapy is the most frequent cause of drug-induced osteoporosis. Objective: The objective of the study was to evaluate bone mineral density (BMD) and bone metabolism in CAH patients. Design: This was a cross-sectional observational study. Setting: The study was conducted at a referral center for pediatric endocrinology. Patients and Other Participants: Thirty young patients with the classical form of CAH (aged 16.4–29.7 yr) treated with glucocorticoid from diagnosis (duration of treatment 16.4–29.5 yr) and 138 healthy controls (aged 16.0–30.0 yr) were enrolled. Main Outcome Measures: BMD was measured in the lumbar spine and whole body by dual-energy x-ray absorptiometry. Bone formation and resorption rates were estimated by serum measurements of bone-specific alkaline phosphatase and C-terminal telopeptide of type I collagen, respectively. Results: CAH patients were shorter than controls (women −6.8 and men −13.3 cm). Therefore, several methods were used to account for the effect of this difference on bone measurements. Whole-body BMD measurements were significantly lower, compared with controls (P < 0.03), after controlling for height (on average −2.5% in females and −9.3% in male patients). No differences were found in lumbar spine measurements. Bone-specific alkaline phosphatase and C-terminal telopeptide of type I collagen serum concentrations were higher in CAH patients than control subjects (P < 0.04). BMD measurements and bone metabolism markers did not correlate with the actual glucocorticoid dose or mean dose over the previous 7 yr. Conclusions: Young adult patients with the classical form of CAH have decreased bone density values, compared with healthy controls. This may put them at risk of developing osteoporosis early in life.

scholarly journals Effects of Six-Week Resistance Training with or without Vibration on Metabolic Markers of Bone Metabolism

2021 ◽  
Vol 18 (18) ◽  
pp. 9860
Author(s):  
Patrick Lau ◽  
Åsa Beijer ◽  
André Rosenberger ◽  
Eckhard Schoenau ◽  
Christoph Stephan Clemen ◽  
...  
Keyword(s):  
Bone Metabolism ◽  
Type I Collagen ◽  
Bed Rest ◽  
Whole Body ◽  
Type I ◽  
Metabolic Markers ◽  
Resistive Exercise ◽  
Procollagen Type ◽  
Amino Terminal ◽  
First Session

Acute and protracted effects of resistive exercise (RE) and resistive exercise with whole-body vibration (RVE) on metabolic markers of bone metabolism were investigated. Twenty-six men participated in a randomized training program including RE (n = 13; age = 23.4 ± 1.4 years) or RVE (n = 13; age = 24.3 ± 3.3 years). During the first session, acute C-terminal telopeptide of type I collagen (CTX) responses decreased by 12.9% (standard deviation, SD 13.7%) after 2 min, followed by a 15.5% (SD 36.0%) increase at 75 min after exercise (both p < 0.001). Procollagen type I amino terminal propeptide (P1NP) increased by 12.9% (SD 9.1%) at 2 min (p < 0.001) but no change occurred at 75 min. Sclerostin showed prolonged responses from 2 to 75 min post-exercise in the first session (p < 0.001). Acute responses at the first session were comparable between groups for CTX and P1NP, acute sclerostin responses were substantially greater in RE than in RVE (p = 0.003). No significant differences were noted in the resting baseline levels of CTX, P1NP, or sclerostin from the beginning to the end of the six-week progressive training. The present study therefore did not demonstrate any sizeable enhancement of bone turnover that could match the effects that have been repeatably made in response to countermeasure exercise during bed rest.

The influence of bisphosphonates on bone turnover markers in patients (pts) with breast cancer (BC)

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 1058-1058
Author(s):  
A. Keller ◽  
K. Heim ◽  
G. Welzel ◽  
P. Findeisen ◽  
M. Neumaier ◽  
...  
Keyword(s):  
Bone Metastases ◽  
Bone Metabolism ◽  
Aromatase Inhibitors ◽  
Type I Collagen ◽  
Collagen Type I ◽  
Bone Resorption Marker ◽  
Type I ◽  
Serum Samples ◽  
Turnover Markers ◽  
The Impact

1058 Background: The relevance of the bone metabolism for the prognosis of BC pts is becoming widely accepted. Bisphosphonates are increasingly used in BC pts as prophylactic (antitumor benefits) or as therapeutic agents for the prevention of skeletal related events (SREs). The bone resorption marker peptide-bound collagen type I cross-links C-telopeptides (ICTP) and the bone formation marker N-terminal propeptide of type I collagen (PINP) may become important tools to monitor the bone metabolism and may be influenced by co-medication. Methods: ICTP and PINP were measured in serum samples (n = 252) under standardized conditions. We included BC pts without (n=118, 58±11 yrs) and with bone metastases (BM, n=23, 64 + 12 yrs). For comparison 111 prostate cancer (PC) pts without (n = 84, 70 ± 6 yrs) and with BM (n = 27, 67 ± 10 yrs) were investigated. Results: The median ICTP (5.41 vs 4.34 ug/l, p = 0.04 [Mann-Whitney test]) and PINP (44.9 vs 36.3 ug/l, p = 0.08) values were higher in BC pts with BM as compared to no BM. The presence of BM (< 3 vs 1–3 mets) increased ICTP and PINP values further, whereas bisphosphonates lead to a significant reduction in PINP to normal values in these pts (58.3 vs 32.8 ug/l, p = 0.01). Tamoxifen increased ICTP (4.85 ± 1.8 ug/l) and decreased PINP (36.7 ± 14.3 ug/l), whereas aromatase inhibitors (AIs) increased ICTP (4.93 ± 1.7 ug/l) and PINP (49.4 ± 24.7 ug/l). The same effects were seen in PC pts with and without BM, LHRH had a similar effect like AIs, whereas the impact of antiandrogens was like tamoxifen. Age and gender had no significant influence on ICTP or PINP in BC and PC pts. Conclusions: Markers of bone metabolism may be useful for the diagnosis and follow-up of pts with BC and PC with and without BM. Bone metastases and aromatase inhibitors increased serum ICTP and PINP, whereas bisphosphonates induced a significant decrease in serum PINP. [Table: see text]

Advantages and limitations of whole-body bone marrow MRI using turbo-STIR sequences in comparison to planar bone scans

2000 ◽  
Vol 39 (06) ◽  
pp. 174-179 ◽  
Author(s):  
N. Manthey ◽  
F. Berger ◽  
H. Sommer ◽  
T. Pfluger ◽  
K. Hahn ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Metastases ◽  
Bone Scintigraphy ◽  
The Body ◽  
Whole Body ◽  
Advantages And Disadvantages ◽  
Slice Orientation ◽  
Mri Protocol ◽  
Bone Scans ◽  
Body Bone

SummaryAt modern MRI tomographs the whole body can be screened for bone marrow metastases within 45 min. Aim of this study was to evaluate the diagnostic advantages and disadvantages of a whole-body bone marrow MRI protocol using Turbo Short Tau Inversion Recovery [STIR] sequences in comparison to planar bone scintigraphy (SZ). Patients and methods: In order to screen for bone metastases within two weeks SZ and whole-body MRI with Turbo-STIR-sequences were performed in 20 patients with known breast cancer. For further evaluation five regions were defined: scull, spine including the pelvis, femora, humeri and ribs including scapulae and sternum. Results: In 9/20 patients neither with SZ nor with MRI bone metastases were detected (staging M0). Among the remaining 11 patients SZ detected 109 and MRI 150 lesions which were typical for bone metastases. All of these 11 patients were staged Ml correspondingly with both methods. Within the thorax (ribs, sternum, scapulae) MRI discovered only 6/17 and within the scull 0/6 lesions which were suspicious for metastases in SZ. Inversely MRI identified much more metastatic lesions than SZ within the femora (20/16), the humeri (14/12) and the spine including the pelvis (110/58). Conclusions: Susceptibility-, truncation*, chemical-shift-, third arm- and particularly pulsation artifacts along with the impossibility to chose slice orientation equally advantageous for all regions of the body cause impaired image quality of MRI whole body scanning. Therefore, concerning the detection rate of bone metastases within the thorax (ribs, sternum and scapulae) and the scull, conventional Turbo-STIR-MRI whole-body scans are even less accurate than conventional planar bone scintigraphy in those regions.

scholarly journals Prospective comparison of the diagnostic accuracy of 18F-FDG PET/MRI, MRI, CT, and bone scintigraphy for the detection of bone metastases in the initial staging of primary breast cancer patients

2021 ◽  
Author(s):  
Nils Martin Bruckmann ◽  
Julian Kirchner ◽  
Lale Umutlu ◽  
Wolfgang Peter Fendler ◽  
Robert Seifert ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Metastases ◽  
Cancer Patients ◽  
Bone Scintigraphy ◽  
Fdg Pet ◽  
Primary Breast Cancer ◽  
Whole Body ◽  
Newly Diagnosed ◽  
Breast Cancer Patients ◽  
Initial Staging

Abstract Objectives To compare the diagnostic performance of [18F]FDG PET/MRI, MRI, CT, and bone scintigraphy for the detection of bone metastases in the initial staging of primary breast cancer patients. Material and methods A cohort of 154 therapy-naive patients with newly diagnosed, histopathologically proven breast cancer was enrolled in this study prospectively. All patients underwent a whole-body [18F]FDG PET/MRI, computed tomography (CT) scan, and a bone scintigraphy prior to therapy. All datasets were evaluated regarding the presence of bone metastases. McNemar χ2 test was performed to compare sensitivity and specificity between the modalities. Results Forty-one bone metastases were present in 7/154 patients (4.5%). Both [18F]FDG PET/MRI and MRI alone were able to detect all of the patients with histopathologically proven bone metastases (sensitivity 100%; specificity 100%) and did not miss any of the 41 malignant lesions (sensitivity 100%). CT detected 5/7 patients (sensitivity 71.4%; specificity 98.6%) and 23/41 lesions (sensitivity 56.1%). Bone scintigraphy detected only 2/7 patients (sensitivity 28.6%) and 15/41 lesions (sensitivity 36.6%). Furthermore, CT and scintigraphy led to false-positive findings of bone metastases in 2 patients and in 1 patient, respectively. The sensitivity of PET/MRI and MRI alone was significantly better compared with CT (p < 0.01, difference 43.9%) and bone scintigraphy (p < 0.01, difference 63.4%). Conclusion [18F]FDG PET/MRI and MRI are significantly better than CT or bone scintigraphy for the detection of bone metastases in patients with newly diagnosed breast cancer. Both CT and bone scintigraphy show a substantially limited sensitivity in detection of bone metastases. Key Points • [18F]FDG PET/MRI and MRI alone are significantly superior to CT and bone scintigraphy for the detection of bone metastases in patients with newly diagnosed breast cancer. • Radiation-free whole-body MRI might serve as modality of choice in detection of bone metastases in breast cancer patients.

Sign in / Sign up

Export Citation Format

Share Document